Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,488,962

« Back to Dashboard

Which drugs does patent 6,488,962 protect, and when does it expire?

Patent 6,488,962 protects GLUMETZA, JENTADUETO XR, PROQUIN XR, SYNJARDY XR, XARTEMIS XR, and GRALISE, and is included in six NDAs.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 6,488,962

Title:	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Abstract:	The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
Inventor(s):	Berner; Bret (El Granada, CA), Louie-Helm; Jenny (Union City, CA)
Assignee:	DepoMed, Inc. (Menlo Park, CA)
Application Number:	09/598,061
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,488,962
Patent Claim Types: see list of patent claims	Dosage form;

Drugs Protected by US Patent 6,488,962

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-002	Jun 3, 2005	AB3	RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y			➤ Sign Up
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-001	Jun 3, 2005	AB3	RX	Yes	No	➤ Sign Up	➤ Sign Up	Y	Y			➤ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

International Family Members for US Patent 6,488,962

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2412671	➤ Sign Up
Germany	60101581	➤ Sign Up
Denmark	1294363	➤ Sign Up
European Patent Office	1294363	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant

Argus Health

McKinsey

Chubb

Accenture

Citi

AstraZeneca

Chinese Patent Office

US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.